Non-Hodgkin Lymphoma Diagnostics Market size will expand at a commendable rate between 2023 and 2032 driven by high demand for advanced treatment options and growing public awareness.
Non-hodgkin lymphoma (NHL) is a type of cancer that develops in lymphoid tissues, primarily lymph nodes. It is one of the most common cancers and accounts for about 4% of all cancer cases in the US. The American Cancer Society estimates that about 80,470 people will be diagnosed with NHL in 2022. Several FDA-approved therapeutic medications and enhanced diagnostic methods are developed to improve treatment outcomes. However, rising medical costs and strict regulatory requirements could restrain industry expansion to some extent.
Non-Hodgkin lymphoma diagnostics market from biopsy testing segment is anticipated to account for a sizable share of the non-Hodgkin lymphoma (NHL) diagnostics market by 2032. Biopsy testing is commonly used in excisional or incisional biopsy procedures. They are frequently employed for diagnosing illnesses such as infections and inflammatory disorders. Since imaging exams do not precisely describe the problem, biopsies are vastly preferred for extra clarity. The introduction of advanced testing methods, such as liquid biopsies, might facilitate market growth over the coming years.
Based on end-use, hospitals are likely to see a high demand for non-Hodgkin lymphoma diagnostics. These healthcare setting have easy accessibility to quick and precise diagnostic tests as well as skilled specialists. This not only reduces the use of unnecessary medications but also shortens hospital stays and improves patient outcomes. The increasing desire of patients to receive cancer diagnoses in hospitals will support segment growth. As per a survey taken in France, 71% of the participants chose hospital over home care as they wanted the best treatments.
The Asia Pacific non-Hodgkin lymphoma diagnostics market will register a sizable revenue share by 2023 driven by rising healthcare spending and a growing patient base. Increased propensity for urban lifestyles and rapid economic development are to blame for the rise in cancer cases across the region. Advancements in the healthcare sector will influence by the availability of high diagnostic facilities and developments in testing methods might advocate regional market expansion.
North America non-Hodgkin lymphoma diagnostics market is also predicted to grow at a commendable rate due to rising cases of cancer and high spending on its diagnostic solutions. become more prevalent in the region. According to the American Cancer Society, around $246 billion is expected to be spent in the U.S. on cancer-related health care by 2030. The industry will be driven by expanding technological developments and investments in the healthcare domain and the presence of robust regulatory frameworks.
Globally, the leading companies operating in the global non-Hodgkin lymphoma diagnostics market include Merit Medical Systems, Thermo Fisher Scientific, LSL HEALTHCARE, INC., Medtronic, Aspire Medical Innovation, Argon Medical, Depuy Synthes (Johnson & Johnson), Merck KGaA, Medplus Inc., PerkinElmer, Inc. (PerkinElmer), Agilent Technologies, Inc., BD, Cardinal Health, and Abbott Laboratories. To increase their market share, these companies are concentrating on crucial business methods like mergers, collaborations, and acquisitions.